IMMUNOGENICITY OF RECOMBINANT BCG VACCINES IN RHESUS MONKEYS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 分枝杆菌载体作为粘膜疫苗提供了相当大的希望，但由于抗原表达差、载体不稳定和预先存在的抗BCG免疫的流行，这些载体的效用迄今为止受到限制。分枝杆菌具有使它们作为潜在的HIV-1疫苗载体具有吸引力的特征。最重要的是，它们已被成功地用作疫苗。减毒的非致病性牛分枝杆菌BCG已被广泛用作结核病（TB）和麻风病的疫苗。它也可以容易地被工程化以稳定地表达转基因。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Mycobacteria vectors offer considerable promise as a mucosal vaccine, but the utility of these vectors has to date been limited because of poor antigen expression, vector instability, and the prevalence of pre-existing Anti-BCG immunity. Mycobacteria have features that make them attractive as potential HIV-1 vaccine vectors. Most importantly, they have been used successfully as vaccines. The attenuated, non-pathogenic Mycobacterium bovis BCG has been widely used as a vaccine for tuberculosis (TB) and leprosy. It can also be readily engineered to stably express transgenes.